Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Salvage Haploidentical HSCT Using Posttransplant Cyclophosphamide for Engraftment Failure
jRCTs031220607Phase 2Recruiting
- Sponsor
- The Japanese Society for Transplantation and Cellular Therapy
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in Bone marrow transplant failure, sponsored by The Japanese Society for Transplantation and Cellular Therapy. Primary endpoint: Overall survival at 1 year. Started Jul 2023; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
Bone marrow transplant failure
Beyond the preview
Go deeper on jRCTs031220607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220607.